NCCN Flash Update: NCCN Guidelines Updated
NCCN has published updates to the NCCN Guidelines for Neuroendocrine Tumors. These NCCN Guidelines are currently available as Version 1.2011.
- For both carcinoid and pancreatic endocrine tumors (islet cell tumors), the management of locoregional unresectable disease and/or distant metastases was revised by organizing recommendations based on disease status rather than based on disease site.
- For carcinoid tumors, upon clinically significant disease progression, the option to consider everolimus was added with a category 3 designation.
- For pancreatic endocrine tumors that are symptomatic or demonstrate clinically significant tumor burden or clinically significant progressive disease, the recommendations for everolimus and sunitinib were changed from category 2B to a category 2A.
For non-functioning adrenal gland tumors, the management recommendations were revised by organizing them based on tumor appearance, features, and size rather than tumor size alone.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.